688658.SH
悦康药业
SSE · Healthcare · Biotechnology · CN
CNY 13.21
−7.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.4B | 2.4B | 3.8B | 4.2B | 4.5B |
| Cost of Revenue | 1.1B | 1.2B | 1.6B | 1.6B | 1.6B |
| Gross Profit | 1.3B | 1.2B | 2.2B | 2.6B | 2.9B |
| Operating Expenses | |||||
| R&D Expense | 435.7M | 441.2M | 374.3M | 351.9M | 344.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 252.0M | 267.0M | 239.9M | 230.3M | 245.3M |
| Selling & Marketing Expense | 756.6M | 703.9M | 1.3B | 1.8B | 2.0B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.5B | 1.5B | 2.0B | 2.4B | 2.6B |
| Cost and Expenses | 2.6B | 2.7B | 3.6B | 4.0B | 4.2B |
| Operating Income (EBIT) | (205.9M) | (234.4M) | 159.1M | 231.8M | 357.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (208.6M) | (237.1M) | 152.4M | 223.3M | 349.5M |
| Income Tax Expense | 54.8M | 37.8M | 31.1M | 35.8M | 10.6M |
| Bottom Line | |||||
| Net Income | (246.2M) | (262.4M) | 123.7M | 184.8M | 335.2M |
| Earnings from Cont. Ops | (263.3M) | (274.8M) | 121.2M | 187.5M | 338.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (246.2M) | (262.4M) | 123.7M | 184.8M | 335.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.55) | (CN¥0.59) | CN¥0.28 | CN¥0.41 | CN¥0.74 |
| Diluted EPS | (CN¥0.55) | (CN¥0.59) | CN¥0.28 | CN¥0.41 | CN¥0.74 |
| Revenue Per Share | CN¥5.13 | CN¥5.50 | CN¥8.56 | CN¥9.31 | CN¥10.03 |
| Shares | |||||
| Basic Shares Outstanding | 472.9M | 444.7M | 441.8M | 450.7M | 453.0M |
| Diluted Shares Outstanding | 472.9M | 444.7M | 441.8M | 450.7M | 453.0M |
| Profitability Metrics | |||||
| EBITDA | — | (28.6M) | 362.7M | 402.1M | 513.4M |
| D&A | — | 205.9M | 203.6M | 170.3M | 155.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026